Concepedia

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Anthony W. Tolcher, Patricia LoRusso, Jennifer A. Arzt, Todd Busman, Guinan Lian, Niki S. Rudersdorf, Carol Ann Vanderwal, Jeffrey F. Waring, Jianning Yang, Kyle D. Holen,

Cancer Chemotherapy and Pharmacology · 2015 · 38 citations · 20 references

DOI

Concepts

References

20

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

, , +16

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Lin Chen, Simon N. Willis, Andrew H. Wei et al. · Molecular Cell · 2005 · 1.8K citations · Full text

, , +13

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

Michael Certo, Victoria Del Gaizo Moore, Mari Nishino et al. · Cancer Cell · 2006 · 1.3K citations · Full text

, , +15

Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak

Simon N. Willis, Jamie I. Fletcher, Thomas Kaufmann et al. · Science · 2007 · 1.1K citations

, , +15